Table 2 Associations between CN expression, clinical parameters and disease-free survival
From: Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer
Clinical parameters | Disease-free survival (months) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total type | Clear-cell carcinoma | Serous carcinoma | Papillary serous cystadenocarcinoma | |||||||||||||
N | Mean | 95% CI | p-value | N | Mean | 95% CI | p-value | N | Mean | 95% CI | p-value | N | Mean | 95% CI | p-value | |
CN expression | ||||||||||||||||
≦50 | 24 | 97.67 | 73.67, 121.66 | 0.41 | 7 | 77.70 | 60.20, 95.20 | 0.27 | 7 | 143.33 | 92.76, 191.53 | 0.43 | 10 | 62.80 | 42.71, 82.89 | 0.89 |
>50 | 17 | 87.15 | 72.12, 102.19 | 10 | 56.29 | 26.30, 86.27 | 2 | 116.39 | 95.55, 160.14 | 5 | 64.60 | 46.88, 82.32 | ||||
Age (years) | ||||||||||||||||
<50 | 26 | 181.38 | 157.41, 205.34 | < 0.01* | 10 | 83.33 | 69.17, 97.50 | 0.07 | 7 | 188.30 | 163.97, 212.63 | 0.04* | 9 | 66.71 | 46.30, 87.12 | 0.50 |
≧50 | 24 | 82.12 | 59.05, 105.19 | 9 | 51.60 | 26.31, 76.87 | 8 | 98.49 | 77.65, 142.24 | 7 | 57.33 | 36.48, 78.19 | ||||
Pathological stage | ||||||||||||||||
I~II | 29 | 167.83 | 141.87, 193.79 | 0.09 | 9 | 76.78 | 57.89, 95.67 | 0.52 | 10 | 168.30 | 123.97, 212.63 | 0.99 | 10 | 73.40 | 60.50, 86.30 | 0.04* |
III~IV | 20 | 68.24 | 48.96, 87.52 | 9 | 64.22 | 39.29, 89.16 | 5 | 86.80 | 56.65, 116.95 | 6 | 40.17 | 14.87, 65.46 | ||||
Tumor size (mm3) | ||||||||||||||||
< 395 | 26 | 132.37 | 97.50, 167.24 | 0.19 | 5 | 75.60 | 59.41, 91.78 | 0.06 | 12 | 154.33 | 103.76, 202.53 | 0.36 | 9 | 65.29 | 43.36, 87.21 | 0.08 |
≧395 | 24 | 86.30 | 72.20, 100.40 | 14 | 42.40 | 7.14, 77.66 | 3 | 96.39 | 75.55, 140.14 | 7 | 58.44 | 38.35, 78.54 | ||||
LN metastasis | ||||||||||||||||
No | 31 | 163.70 | 137.35, 190.06 | 0.08 | 11 | 72.64 | 54.13, 91.15 | 0.55 | 10 | 168.30 | 123.97, 212.63 | 0.99 | 10 | 73.40 | 60.50, 86.30 | 0.04* |
Yes | 19 | 65.44 | 45.02, 85.86 | 8 | 58.75 | 29.89, 87.61 | 5 | 86.80 | 56.65, 116.95 | 6 | 40.17 | 14.87, 65.46 | ||||
Distant metastasis | ||||||||||||||||
No | 48 | 153.55 | 130.07, 177.03 | 0.02* | 18 | 69.19 | 52.48, 85.89 | 0.17 | 15 | 167.80 | 131.11, 204.49 | ─ | 15 | 64.20 | 49.30, 79.10 | 0.15 |
Yes | 2 | 21.00 | 19.04, 22.96 | 1 | 22.00 | 22.00, 22.00 | 0 | ─ | ─ | 1 | 20.00 | 20.00, 20.00 | ||||
Ascites | ||||||||||||||||
No | 26 | 153.63 | 121.72, 185.54 | 0.63 | 10 | 66.00 | 43.09, 88.91 | 0.98 | 11 | 164.33 | 113.76, 212.53 | 0.27 | 5 | 77.80 | 66.93, 88.67 | 0.29 |
Yes | 24 | 75.63 | 59.23, 92.02 | 9 | 67.44 | 44.19, 90.70 | 4 | 97.49 | 76.65, 141.24 | 11 | 54.00 | 34.39, 73.61 | ||||
Chemotherapeutic response | ||||||||||||||||
No | 2 | 51.00 | 0, 105.05 | 0.60 | 1 | 82.00 | 82.00, 82.00 | 0.48 | 0 | ─ | ─ | ─ | 1 | 20.00 | 20.00, 20.00 | 0.07 |
Yes | 37 | 95.81 | 77.57, 114.05 | 15 | 64.06 | 41.89, 86.23 | 10 | 102.80 | 70.29, 135.31 | 12 | 65.25 | 49.35, 81.15 | ||||
Chemotherapeutic resistance | ||||||||||||||||
No | 21 | 126.95 | 109.94, 143.96 | < 0.01* | 5 | 73.20 | 50.76, 95.64 | 0.12 | 5 | 141.30 | 70.29, 212.31 | 0.02* | 11 | 75.09 | 63.04, 87.15 | < 0.01* |
Yes | 11 | 31.95 | 16.56, 47.33 | 5 | 32.60 | 8.37, 56.83 | 1 | 32.00 | 32.00, 32.00 | 5 | 30.20 | 8.41, 51.99 | ||||
CA125 (U/ml) | ||||||||||||||||
< 324 | 24 | 133.50 | 97.04, 169.96 | 0.18 | 11 | 78.46 | 62.08, 94.83 | 0.27 | 5 | 162.44 | 111.65, 213.24 | 0.85 | 8 | 71.13 | 54.12, 88.13 | 0.28 |
≧324 | 24 | 88.03 | 75.20, 100.86 | 7 | 56.00 | 26.65, 85.35 | 9 | 90.20 | 66.01, 114.39 | 8 | 51.75 | 29.15, 74.35 | ||||
CA19–9 (U/ml) | ||||||||||||||||
< 21.55 | 24 | 147.26 | 112.14, 182.39 | 0.86 | 8 | 71.38 | 47.59, 95.16 | 0.71 | 8 | 153.29 | 93.79, 212.78 | 0.51 | 8 | 55.38 | 35.44, 75.31 | 0.55 |
≧21.55 | 23 | 105.67 | 84.02, 127.31 | 7 | 66.06 | 42.89, 89.23 | 7 | 124.50 | 96.08, 152.92 | 7 | 64.00 | 40.54, 87.46 | ||||
CA72–4 (U/ml) | ||||||||||||||||
< 7.89 | 25 | 174.20 | 147.38, 201.03 | 0.04* | 8 | 80.00 | 59.83, 100.17 | 0.21 | 9 | 164.33 | 115.76, 212.91 | 0.80 | 8 | 74.75 | 59.62, 89.88 | 0.05* |
≧7.89 | 24 | 69.33 | 52.59, 86.08 | 10 | 60.74 | 38.11, 83.37 | 6 | 89.67 | 64.02, 115.31 | 8 | 47.25 | 25.78, 76.36 | ||||
AFP (ng/mL) | ||||||||||||||||
< 2.9 | 25 | 148.04 | 113.12, 182.97 | 0.82 | 7 | 79.00 | 66.73, 91.27 | 0.31 | 6 | 183.33 | 145.14, 221.52 | 0.30 | 12 | 65.25 | 49.35, 81.15 | 0.49 |
≧2.9 | 24 | 105.84 | 86.19, 125.49 | 11 | 61.10 | 37.54, 84.64 | 9 | 99.83 | 57.55, 142.12 | 4 | 50.00 | 16.57, 83. 44 | ||||
CEA (ng/mL) | ||||||||||||||||
< 1.48 | 24 | 180.33 | 155.28, 205.39 | 0.03* | 10 | 81.49 | 69.17, 97.50 | 0.02* | 8 | 177.14 | 128.41, 225.88 | 0.67 | 6 | 58.67 | 37.69, 79.65 | 0.39 |
≧1.48 | 24 | 89.07 | 66.13, 112.02 | 8 | 31.60 | 16.31, 56.87 | 7 | 109.38 | 76.09, 142.66 | 9 | 68.44 | 49.41, 87.48 | ||||